exenatide + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Oct 1, 2005 → Jun 1, 2007
NCT ID
NCT00241423About exenatide + Placebo
exenatide + Placebo is a phase 2 stage product being developed by Eli Lilly for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT00241423. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01140893 | Phase 2/3 | UNKNOWN |
| NCT01364584 | Pre-clinical | Completed |
| NCT00845507 | Approved | Completed |
| NCT00603239 | Phase 3 | Completed |
| NCT00516074 | Phase 3 | Completed |
| NCT00500370 | Phase 2 | Completed |
| NCT00456885 | Approved | Completed |
| NCT00667732 | Approved | Completed |
| NCT00375492 | Phase 3 | Completed |
| NCT00324363 | Phase 3 | Completed |
| NCT00241423 | Phase 2 | Completed |
| NCT00099320 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus